OSE Immunotherapeutics Responds to Nantes Court Decision
OSE Immunotherapeutics, a prominent biotech firm, recently acknowledged an important ruling made by the Nantes Commercial Court. This decision revolved around claims concerning the actions of a group of minority shareholders. A response was articulated to clarify the implications of this ruling.
Strategic Direction Post-Court Decision
In light of the court's decision, OSE Immunotherapeutics has placed emphasis on maintaining focus on its strategic objectives. Rather than pursuing an appeal, the Board has determined that the best course of action is to concentrate on upcoming plans, specifically, the approaching General Meeting. This meeting is scheduled to occur without the disruption of prolonged legal battles, allowing it to proceed smoothly and as intended.
Board's Commitment to Transparency
The Board of Directors stands firm in its confidence regarding the legitimacy of their positions and is committed to clarity and transparency with all shareholders. They have remarked that the prioritization of corporate governance and shareholder rights is crucial, especially during this pivotal period for the company.
Addressing Voting Rights Concerns
A critical issue arose during the preparations for the General Meeting when the Board discovered a significant error that impacted the calculation of voting rights. This issue was tied to the vesting period for free shares and was incorrectly portrayed by the minority shareholder group. The Board has taken immediate steps to rectify this mistake and clarified that it was due to a misunderstanding by an external advisor rather than any misconduct on their part.
Restoring Confidence Among Shareholders
OSE Immunotherapeutics is dedicated to restoring confidence among its shareholders following the recent challenges. By promptly addressing the voting rights error and committing to transparency, the company aims to foster trust and demonstrate accountability in its practices. They are eager to ensure that all shareholders feel informed and valued as the General Meeting approaches.
About OSE Immunotherapeutics
OSE Immunotherapeutics is at the forefront of biotechnological advancements, specializing in immuno-oncology and immuno-inflammation. The company is dedicated to developing innovative therapies that meet critical patient needs, partnering with notable academic and biopharmaceutical organizations to propel new treatments into the market. Headquartered across Nantes and Paris, OSE Immunotherapeutics is listed on Euronext, making it accessible to a broad range of investors.
Frequently Asked Questions
What was the Nantes Commercial Court's ruling about?
The court ruled against OSE Immunotherapeutics in a case involving claims from minority shareholders regarding their actions.
What is the next step for OSE Immunotherapeutics after the court decision?
The company plans to focus on its strategic plans and proceed with its General Meeting without appealing the court's decision.
How has the Board of Directors responded to shareholders’ concerns?
The Board has reaffirmed its commitment to transparency and has addressed a critical voting rights error to restore shareholder confidence.
What does OSE Immunotherapeutics specialize in?
OSE Immunotherapeutics specializes in developing innovative treatments in immuno-oncology and immuno-inflammation.
Where can I find more information about OSE Immunotherapeutics?
For more details about their projects and updates, visit the company's official website at http://ose-immuno.com.
